Table 1.
Baseline characteristics
| BRAF inhibitor–naive cohort n = 63 |
Vemurafenib monotherapy–PD cohort n = 66 |
|
|---|---|---|
| Median age, years (range) | 56.0 (21–74) | 53.0 (19–88) |
| Male, n (%) | 35 (56) | 42 (64) |
| ECOG performance status, n (%) | ||
| 0 | 41 (65) | 23 (35) |
| 1 | 22 (35) | 43 (65) |
| Disease stage, n (%) | ||
| Unresectable stage IIc | 7 (11) | 3 (5) |
| Stage IVa | 3 (5) | 4 (6) |
| Stage IVb | 9 (14) | 5 (8) |
| Stage IVc | 44 (70) | 54 (82) |
| Elevated LDH, n (%) | 29 (46) | 39 (62)a |
| Treatment status | ||
| Previously untreated | 43 (68) | N/A |
| Previously treated, BRAF inhibitor–naive | 20 (32) | N/A |
| Median follow-up, months (range) | 28.0 (2.7–69.2) | 8.4 (1.6–76.4) |
Abbreviations: ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase; PD, progressive disease.
a
Baseline data available for 63 patients.